Intelligent Bio Solutions Inc. (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, has revealed key performance indicators from its operations in the United Kingdom. These indicators have contributed to the company’s growth as the drug screening industry continues to battle drug test cheating and seeks simpler, faster, non-invasive, and more cost-effective solutions.
During the twelve months ending in the second quarter of 2024, Intelligent Bio Solutions Inc. recorded a cumulative net loss of $-13 million, resulting in a negative return on investment (ROI) of -322.78%. This figure places the company below 332 other healthcare sector companies that had a higher return on investment.
However, there is progress in the company’s ROI ranking. In the previous quarter ending December 31, 2023, the company’s overall ROI ranking improved from 4367 to 2348.
Furthermore, on October 2, 2023, Intelligent Bio Solutions Inc. celebrated the successful pricing of a $4 million underwritten public offering. This achievement will assist the company in advancing its transformative healthcare technologies. The proceeds raised from the public offering will play a crucial role in accelerating the development and commercialization of the company’s cutting-edge testing solutions.
Comments